These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 19672004

  • 1. [Application of aptamers to medicine: pharmacological profile and results of clinical trials on pegaptanib sodium (Macugen) for age-related macular degeneration].
    Nagaoka M, Tahara M, Esaka E, Oishi M, Nakane M.
    Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):87-95. PubMed ID: 19672004
    [No Abstract] [Full Text] [Related]

  • 2. Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF).
    Katz B, Goldbaum M.
    Int Ophthalmol Clin; 2006 Aug; 46(4):141-54. PubMed ID: 17060800
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP.
    Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
    [Abstract] [Full Text] [Related]

  • 6. Pegaptanib sodium for the treatment of age-related macular degeneration.
    Apte RS.
    Expert Opin Pharmacother; 2008 Feb; 9(3):499-508. PubMed ID: 18220500
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical update: new treatments for age-related macular degeneration.
    Wong TY, Liew G, Mitchell P.
    Lancet; 2007 Jul 21; 370(9583):204-206. PubMed ID: 17658379
    [No Abstract] [Full Text] [Related]

  • 9. Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
    Calvo-González C, Reche-Frutos J, Donate-López J, García-Feijoó J, Leila M, Fernández-Pérez C, Garcia-Sánchez J.
    Br J Ophthalmol; 2008 Jan 21; 92(1):74-5. PubMed ID: 18156376
    [Abstract] [Full Text] [Related]

  • 10. Pegaptanib for the treatment of age-related macular degeneration.
    Zhou B, Wang B.
    Exp Eye Res; 2006 Sep 21; 83(3):615-9. PubMed ID: 16678158
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration.
    Basile AS, Hutmacher M, Nickens D, Nielsen J, Kowalski K, Whitfield L, Masayo O, Nakane M.
    J Clin Pharmacol; 2012 Aug 21; 52(8):1186-99. PubMed ID: 21947371
    [Abstract] [Full Text] [Related]

  • 16. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun 21; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 17. Macugen treatment for wet age-related macular degeneration.
    Tobin KA.
    Insight; 2006 Jun 21; 31(1):11-4. PubMed ID: 16817567
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.